title: PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes.
authors.forename: M Y
authors.initials: MY
authors.lastname: Follo
authors.forename: C
authors.initials: C
authors.lastname: Finelli
authors.forename: C
authors.initials: C
authors.lastname: Bosi
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: S
authors.initials: S
authors.lastname: Mongiorgi
authors.forename: M
authors.initials: M
authors.lastname: Baccarani
authors.forename: L
authors.initials: L
authors.lastname: Manzoli
authors.forename: W L
authors.initials: WL
authors.lastname: Blalock
authors.forename: A M
authors.initials: AM
authors.lastname: Martelli
authors.forename: L
authors.initials: L
authors.lastname: Cocco
mesh_terms: D001374:Azacitidine / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000378:metabolism*; D010716:Phosphatidylinositols / Q000378:metabolism*; D054799:Phospholipase C beta / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*
chemical_list: D004791:Enzyme Inhibitors; D010716:Phosphatidylinositols; D051057:Proto-Oncogene Proteins c-akt; C518033:PLCB1 protein, human; D054799:Phospholipase C beta; D001374:Azacitidine